Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Lung Cancer Update
00:00
IBI, Do You Want to Continue?
The ideal biomarker test, in my opinion, for med X on 14 skipping alteration is really an RNA-based assay. And so the next question is about her two mutant non-tumultil lung cancer. In which line of treatment do you administer targeted therapy to your patients? And how do you select between cat matinib and to pot nib? I think that we're very fortunate, I will say, non-small lung cancer, to have all these targets and all these great therapies.
Transcript
Play full episode
